Intraoperative cell salvage vs transfusion in ovarian cancer

Not Applicable

Completed

• Conditions: Cancer; Specialty: Cancer, Primary sub-specialty: Gynae; UKCRC code/ Disease: Cancer/ Malignant neoplasms of female genital organs; Ovarian cancer

• Registration Number: ISRCTN19517317
• Lead Sponsor: Royal Cornwall Hospitals NHS Trust

Brief Summary

2018 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/30389760 protocol (added 01/11/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-11
• Study Completion: 2018-06-30
• Last Update Posted: 5 June 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 57

Inclusion Criteria

1. 18 years old or over
2. Suspected or confirmed ovarian cancer (newly diagnosed) requiring cytoreductive surgery, whether primary or interval (following chemotherapy)
3. CT scan evidence (with or without clinical evidence) compatible with FIGO stage III/IV ovarian cancer/ primary peritoneal cancer at presentation*
4. ECOG Performance Status 0-1
5. Willing to participate and able to give written informed consent

*CT features of pelvic mass (or features suggestive of primary peritoneal cancer) and extrapelvic involvement including ascites, omental disease, peritoneal thickening, bowel surface and/or mesentery involvement, enlarged pelvic and para-aortic lymph nodes, evidence of disease on diaphragm

Exclusion Criteria

1. Diagnosis of concurrent malignancy
2. Pregnant
3. Donor transfusion during the week prior to surgery
4. Haemoglobinopathies (e.g. sickle cell, thalassaemia)
5. Unwilling to accept donor blood (e.g. on religious grounds)

Study & Design

• Study Type: Interventional
• Study Design: Not specified